Ablynx: Clinical Trial Update (Ablynx) - Jul 8, 2016 - "Vobarilizumab Phase IIb RA monotherapy study"; "Conclusions from topline results – week 12"; "Very encouraging efficacy data for vobarilizumab with ACR20, ACR50 and ACR70 scores of up to 81%, 49% and 24%, respectively"; "Rapid improvement in patients’ physical function based on the change from baseline in HAQ-DI score"; "Robust DAS28CRP data for vobarilizumab with up to 60% of patients in either clinical remission or low disease activity at week 12 compared to 43% for open-label tocilizumab"; "Favourable safety profile at all administered doses"
P2b data • Immunology
|